Nephrotoxicity With Vancomycin in the Pediatric Population: A Systematic Review and Meta-Analysis

Area of Science:

• Pharmacology
• Nephrology
• Pediatric Medicine

Background:

• Vancomycin is a critical antibiotic for treating methicillin-resistant Staphylococcus aureus (MRSA) infections in children.
• Vancomycin exposure is associated with an increased risk of nephrotoxicity, necessitating careful monitoring.
• Predicting and mitigating vancomycin-induced nephrotoxicity in pediatric populations is crucial for patient safety.

Purpose of the Study:

• To systematically review predictors of vancomycin-associated nephrotoxicity in pediatric patients.
• To conduct a meta-analysis evaluating the impact of vancomycin trough concentrations ≥15 mg/L on nephrotoxicity.
• To identify key risk factors contributing to vancomycin-induced kidney injury in children.

Main Methods:

• A comprehensive literature search was conducted across major databases (PubMed, Cochrane Library, Embase, Web of Sciences).
• Included studies were randomized clinical trials and observational studies focusing on pediatric patients, vancomycin troughs, and nephrotoxicity.
• Studies were excluded if they did not measure troughs or used a different threshold than 15 mg/L for vancomycin levels.

Main Results:

• Ten studies were included in the meta-analysis, all with normal baseline serum creatinine.
• Elevated vancomycin trough levels (≥15 mg/L) were a significant predictor of nephrotoxicity, increasing risk by 2.7-fold (OR, 2.71).
• Nephrotoxicity risk was further elevated in pediatric intensive care unit (PICU) patients (OR, 3.61).

Conclusions:

• Higher vancomycin trough levels are linked to increased nephrotoxicity in pediatric patients.
• Other contributing factors to vancomycin-induced nephrotoxicity include ICU admission, hypovolemia, and concurrent use of nephrotoxic drugs.
• Optimizing vancomycin dosing and monitoring for these risk factors are essential in pediatric care.